Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 15/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12427118 | 0.85 | ALDH1A1 (0.51) | ALDH1A1CYP19A1TP53HTT | |
| SCHEMBL792454 | 0.80 | ALDH1A1 (0.53) | ALDH1A1CYP19A1HTTMAPT | |
| SCHEMBL4532457 | 0.80 | ALDH1A1 (0.55) | ALDH1A1CYP19A1TP53HTT | |
| SCHEMBL4229386 | 0.79 | ALDH1A1 (0.49) | ALDH1A1TP53MAPT | |
| SCHEMBL3647032 | 0.79 | ALDH1A1 (0.49) | ALDH1A1CYP19A1HTTMAPT | |
| SCHEMBL11089995 | 0.78 | ALDH1A1 (0.54) | ALDH1A1CYP19A1TP53HTTMAPT | |
| SCHEMBL28886071 | 0.78 | ALDH1A1 (0.58) | ALDH1A1CYP19A1TP53HTTMAPT | |
| SCHEMBL6278023 | 0.78 | ALDH1A1 (0.54) | ALDH1A1CYP19A1TP53HTT | |
| SCHEMBL10252934 | 0.74 | ALDH1A1 (0.36) | ALDH1A1MAPT | |
| SCHEMBL20968400 | 0.73 | ERN1 (0.50) | ALDH1A1TP53HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| US-20090036444-A1 | 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036444-A1 | 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor | GTF3C5, ZC3HAV1, POLI | ALDH1A1 596/4885CYP19A1 2916/4885TP53 886/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | ALDH1A1 750/4885CYP19A1 2500/4885TP53 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.